Evidence map›Paper›PMID 40014787›Full record

ArticleRadiology and oncology2025

Early-time-point

Nezka Hribernik, Katja Strasek, Andrej Studen, Katarina Zevnik, Katja Skalic, Robert Jeraj, Martina Rebersek

Abstract read
In one paragraph

Article in Radiology and oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nezka Hribernik1Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Katja Strasek3Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, Slovenia.
Andrej Studen3Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, Slovenia.
Katarina Zevnik7Department of Nuclear Medicine, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Katja Skalic7Department of Nuclear Medicine, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Robert Jeraj3Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, Slovenia.
Martina Rebersek1Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.

Funding

University of Wisconsin Prostate SPOREP50CA269011 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI DAVID F. JARRARD, DOUGLAS G. MCNEEL · 2023 to 2026
$10.6M
NCI NIH HHS P50 CA269011
6 · The paper itself

Abstract

backgroundA considerable proportion of metastatic melanoma (mM) patients do not respond to immune checkpoint inhibitors (ICIs). There is a great need to develop noninvasive biomarkers to detect patients, who do not respond to ICIs early during the course of treatment. The aim of this study was to evaluate the role of early [ PATIENTS AND

methods. In this prospective noninterventional clinical study, mM patients receiving ICIs regularly underwent

resultsOverall, 71 patients were included. The median follow-up was 37.1 months (952% CI = 30.1-38.0). Three (4%) patients had only baseline scans due to rapid disease progression and death prior to W4

conclusionsEvaluation of mM patients with early

Indexed as

Fluorodeoxyglucose F18Immune Checkpoint InhibitorsMelanomaPositron Emission Tomography Computed TomographySkin NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansImmunotherapyMaleMiddle AgedPrognosisProspective StudiesBiomarkers, TumorFluorodeoxyglucose F18Immune Checkpoint InhibitorsRadiopharmaceuticalsearly time-point 18F-FDG-PET/CTimmune-checkpoint inhibitorimmune-related adverse effects metastatic melanomaprognostic biomarkers

Identifiers

PMID40014787
PMCPMC11867565

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.